Esperion Therapeutics (ESPR) Shares are Up 2.67%

Esperion Therapeutics (ESPR) has been under a strong bear grip, hence the stock is down -2.78% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 2.23% in the past 1 week. The stock has risen by 2.67% in the past week indicating that the buyers are active at lower levels, but the stock is down -0.36% in the past 4 weeks.

Esperion Therapeutics (NASDAQ:ESPR): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $11.29 and $10.93 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $11.53. The buying momentum continued till the end and the stock did not give up its gains. It closed at $11.15, notching a gain of 1.64% for the day. The total traded volume was 368,452 . The stock had closed at $10.97 on the previous day.

The stock has recorded a 20-day Moving Average of 0.92% and the 50-Day Moving Average is 18.61%. Esperion Therapeutics, Inc. has dropped 24.92% during the last 3-month period . Year-to-Date the stock performance stands at -49.91%.

Esperion Therapeutics (ESPR) : The most positive equity analysts on Esperion Therapeutics (ESPR) expects the shares to touch $64, whereas, the least positive believes that the stock will trade at $11 in the short term. The company is covered by 10 Wall Street Brokerage Firms. The average price target for shares are $23.3 with an expected fluctuation of $16.26 from the mean.


Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardio-metabolic risk markers. The Companys primary activities include conducting research and development activities, including nonclinical, preclinical and clinical testing, performing business and financial planning, recruiting personnel, and raising capital. ETC-1002, the Companys lead product candidate, is an orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with other LDL-cholesterol lowering therapies currently available. ETC-1002 is being developed for patients with hypercholesterolemia. One completed Phase IIb clinical study and a second that is nearing completion build upon a Phase I and Phase II clinical development program for ETC-1002.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.